Company Encyclopedia
View More
name
CardieX Limited
CDX.AU
News
View More

Cardiex Initiates Unmarketable Parcel Share Buy-Back

Cardiex Limited has announced an unmarketable parcel share buy-back, allowing shareholders with holdings valued at less than A$500 to sell their shares back to the company at A$0.03 per share. This initiative aims to streamline operations by canceling these shares once transferred. Eligible shareholders must submit a retention form by October 13, 2025, if they wish to retain their shares, with the buy-back concluding by October 23, 2025. Cardiex focuses on advancing medical technology for vascular health and is listed on the ASX (AU:CDX).

Tip Ranks·
Tip Ranks·

Cardiex Successfully Raises $6.5 Million Through Entitlement Offer

Cardiex Limited has successfully raised $6.5 million through a fully underwritten entitlement offer, which garnered a 50.3% take-up from shareholders. The funds will support the company's operations in the medical technology sector, focusing on vascular health. Cardiex is listed on the Australian Stock Exchange (ASX:CDX) and offers products for hypertension and cardiovascular diseases, utilizing its SphygmoCor® technology.

Tip Ranks·
Tip Ranks·

Cardiex Unveils Cardiology Report in CONNEQT App, Enhancing Heart Health Management

Cardiex Limited has launched a new Cardiology Report feature in its CONNEQT App, available on the Apple App Store. This feature provides users with a comprehensive cardiovascular health assessment, translating clinically validated biomarkers into an easy-to-understand format. It aims to enhance proactive heart health management, increase user engagement, and create future monetization opportunities. Cardiex focuses on advancing medical technology in vascular health and is listed on the Australian Stock Exchange (ASX: CDX).

Tip Ranks·
Tip Ranks·